Thiotepa

Generic Name: Thiotepa

Brand Names: Tepadina, Thiotepa Riemser

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₃PS

CAS Number: 52-24-4

Unique Ingredient Identifier: 905Z5W3GKH

Background: N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

Indication: ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions: Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion

Clinical Trials

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma
Non-Hodgkin's Lymphoma
Leukemia
Myelodysplastic Syndrome

Interventions: Biological: Palifermin
Biological: Lupron
Procedure: peripheral blood stem cell transplantation
Radiation: Total-Body Irradiation (TBI)
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Degarelix

First Posted Date: 2012-12-11

Last Posted Date: 2025-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 82

Registration Number: NCT01746849

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia in Remission
Chronic Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Cyclophosphamide
Drug: Cyclosporine
Biological: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Drug: Thiotepa
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2012-09-21

Last Posted Date: 2021-07-06

Lead Sponsor: Nohla Therapeutics, Inc.

Target Recruit Count: 163

Registration Number: NCT01690520

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 5 locations

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Not Applicable

Terminated

Conditions: Acute Leukemia
Chronic Leukemia
Myelodysplastic Syndrome
Non-Hodgkins Lymphoma

Interventions: Radiation: total-body irradiation (TBI)
Drug: thiotepa
Drug: fludarabine phosphate
Drug: melphalan
Biological: anti-thymocyte globulin
Procedure: allogeneic hematopoietic stem cell transplantation
Biological: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2012-05-15

Last Posted Date: 2018-08-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT01598025

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: thiotepa
Procedure: stem cell transplant
Drug: G-CSF

First Posted Date: 2012-01-18

Last Posted Date: 2021-08-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 113

Registration Number: NCT01511562

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 123 locations

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Not Applicable

Completed

Conditions: Ewing's Family Tumors
Renal Tumors
Hepatoblastoma
Rhabdomyosarcoma
Soft Tissue Sarcoma
Primary Malignant Brain Neoplasms
Retinoblastoma
Medulloblastoma
Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)
Atypical Teratoid/Rhabdoid Tumor (AT/RT)

Interventions: Drug: Ifosfamide
Drug: Etoposide
Drug: Mesna
Biological: G-CSF
Drug: Anti-seizure prophylaxis
Drug: Busulfan
Drug: Melphalan
Drug: Ursodiol
Drug: Paclitaxel
Drug: Thiotepa
Drug: Carboplatin
Biological: Autologous stem cell infusion
Procedure: Leukapheresis
Radiation: Radiation

First Posted Date: 2012-01-06

Last Posted Date: 2024-02-26

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 44

Registration Number: NCT01505569

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Phase 1

Terminated

Conditions: Acute Leukemia
Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes
Non-Hodgkin's Lymphoma
Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy
Myeloma
Hematologic Malignancies
Hodgkin's Lymphoma

Interventions: Drug: Fludarabine
Drug: Thiotepa
Radiation: Total Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Melphalan
Device: Hematopoietic stem cell transplantation (HSCT)

First Posted Date: 2011-05-09

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 8

Registration Number: NCT01350258

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Multiple Myeloma
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Thiotepa
Radiation: total body irradiation
Drug: Busulfan
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Clofarabine
Procedure: (CliniMACS) T-cell depleted PBSC Transplant

First Posted Date: 2010-05-07

Last Posted Date: 2022-08-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 422

Registration Number: NCT01119066

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia (AML)
Leukemia, Acute
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelogenous Leukemia (CML)
Non-Hodgkin Lymphoma (NHL)

Interventions: Drug: Regulatory T-cells
Drug: Conventional T-cells
Drug: Melphalan
Drug: Thiotepa
Device: Fludarabine
Drug: Anti-thymocyte globulin, rabbit
Drug: CliniMACS CD34 Reagent System

First Posted Date: 2010-01-15

Last Posted Date: 2018-06-27

Lead Sponsor: Everett Meyer

Target Recruit Count: 10

Registration Number: NCT01050764

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Clofarabine for remission induction
Drug: Etoposide for remission induction
Drug: Cyclophosphamide for remission induction
Drug: Clofarabine in conditioning before transplantation
Drug: Thiotepa in conditioning before transplantation
Drug: Melfalan in conditioning before transplantation
Procedure: Haploidentical transplantation of T-cell depleted graft
Procedure: Donor lymphocyte infusion

First Posted Date: 2009-12-04

Last Posted Date: 2021-02-21

Lead Sponsor: Lund University Hospital

Target Recruit Count: 7

Registration Number: NCT01025778

Locations: 🇸🇪
Lund University Hospital, Lund, Sweden

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Phase 2

Completed

Conditions: Central Nervous System Lymphoma

Interventions: Drug: Methotrexate
Radiation: radiotherapy
Drug: Ara-C
Drug: Rituximab
Drug: BCNU
Other: APBSCT
Drug: Thiotepa

First Posted Date: 2009-11-11

Last Posted Date: 2017-08-23

Lead Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Target Recruit Count: 126

Registration Number: NCT01011920

Locations: 🇨🇭
IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇩🇪
Uniklinik Freiburg, Freiburg, Germany

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy